This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/chemspider/
n8http://linked.opendata.cz/resource/drugbank/mixture/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://www.drugs.com/mtm/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/kegg-compound/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/pubchem-compound/
n22http://linked.opendata.cz/ontology/mesh/
n4http://linked.opendata.cz/ontology/drugbank/
n7http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01619/identifier/drugbank/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01619
rdf:type
n4:Drug
n4:description
Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures.
n4:group
approved
n4:indication
Used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold.
owl:sameAs
n6:DB01619 n13:DB01619
dcterms:title
Phenindamine
adms:identifier
n10:50089147 n11:10817 n12:PA164750491 n14:46508187 n17:11291 n18:DB01619 n19:C07790
n4:mechanismOfAction
Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release.
n4:synonym
Phenindamine Nolahist Thephorin Phenindaminum Fenindamina Phenindiamine
n4:toxicity
Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures.
n4:foodInteraction
Take with food to reduce irritation. Avoid alcohol.
n4:mixture
n8:271B5CD1-363D-11E5-9242-09173F13E4C5
n22:hasConcept
n23:M0046968
foaf:page
n21:phenindamine.html
n4:IUPAC-Name
n7:271B5CD6-363D-11E5-9242-09173F13E4C5
n4:InChI
n7:271B5CDC-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n7:271B5CDB-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n7:271B5CD8-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n7:271B5CD9-363D-11E5-9242-09173F13E4C5
n4:SMILES
n7:271B5CDA-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n7:271B5CD4-363D-11E5-9242-09173F13E4C5
n4:logP
n7:271B5CD2-363D-11E5-9242-09173F13E4C5 n7:271B5CD5-363D-11E5-9242-09173F13E4C5
n4:logS
n7:271B5CD3-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:R06AX04
n4:H-Bond-Acceptor-Count
n7:271B5CE2-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n7:271B5CE3-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n7:271B5CDD-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n7:271B5CDE-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n7:271B5CE0-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n7:271B5CDF-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n7:271B5CE1-363D-11E5-9242-09173F13E4C5
n4:affectedOrganism
Humans and other mammals
n4:casRegistryNumber
82-88-2
n4:category
n4:Bioavailability
n7:271B5CE8-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n7:271B5CEA-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n7:271B5CEB-363D-11E5-9242-09173F13E4C5
n4:Melting-Point
n7:271B5CEC-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n7:271B5CE7-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n7:271B5CE6-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n7:271B5CE9-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n7:271B5CD7-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n7:271B5CE4-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n7:271B5CE5-363D-11E5-9242-09173F13E4C5